Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1CNS 1

Conditions

Neuroblastoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Hepatoblastoma 1

Interventions

Etoposide 6Ifosfamide 5Vincristine 4Radiotherapy 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Doxorubicin 4Cyclophosphamide 4Topotecan 2trioctyl phosphine oxide 1indolepropanol phosphate 1imetelstat 1etoposide phosphate 1Vinorelbine 1Vinblastine 1Trabectedin 1Thrombopoietin 1Radiosurgery 1Radiation 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1Microarray Analysis 1Mesna 1MLN 8237 1Irinotecan 1Immunohistochemistry 1Glutamine 1Gene Expression Profiling 1GRN163L peptide 1Electroacupuncture 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Neuroectodermal Tumors, Primitive, Peripheral × MLN 8237 × Clear all
NCT01154816 2020-05-13

Alisertib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Leukemia

Children's Oncology Group

Phase 2 Completed
118 enrolled 24 charts
CNSGastrointestinalLymphoidOther hematologic neoplasmSarcoma

Neuroblastoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡